Ocular surface changes associated with belantamab mafodotin treatment
Graefes Arch Clin Exp Ophthalmol
.
2023 Nov;261(11):3201-3204.
doi: 10.1007/s00417-023-06094-1.
Epub 2023 May 22.
Authors
Seyyedehfatemeh Ghalibafan
1
,
Kwaku A Osei
1
,
James E Hoffman
2
,
Alfonso L Sabater
3
Affiliations
1
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
2
Department of Medicine, Division of Hematology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
3
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA. asabater@med.miami.edu.
PMID:
37212873
DOI:
10.1007/s00417-023-06094-1
No abstract available
Keywords:
Belantamab mafodotin; Corneal toxicity; Dry eye; Multiple myeloma; Tear Film.
Grants and funding
P30EY014801/NIH Center Core Grant